Effect of Helicobacter pylori eradication on insulin resistance in patients with pre-diabetes and type 2 diabetes
- Conditions
- Impaired glucose tolerance Impaired fasting glucose Type 2 diabetes Helicobacter pylori infection
- Registration Number
- JPRN-UMIN000007811
- Lead Sponsor
- Chigasaki Municipal Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Not provided
1)Patients who initiated or changed antidiabetic drugs within 3 months prior to the study entry. 2)Patients who initiated or changed antidyslipidemic drugs within 3 months prior to the study entry. 3)Patients who initiated or changed antiinflammatory drugs within 3 months prior to the study entry. 4)Patients receiving insulin therapy. 5)Patients with gastric or duodenal ulcer in the acute phase. 6)Patients with severe infection or severe trauma. 7)Patients with malignancy. 8)Patients during pregnancy or lactation. 9)Patients with severe liver dysfunction. 10)Patients with severe renal insufficiency. 11)Patients receiving steroid therapy. 12)Patients who were allergic to HP eradication drugs. 13)Patients incapable of informed consent. 14)Patients determined to be inappropriate by physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Insulin resistance (fasting serum insulin levels and homeostasis model assessment of insulin resistance (HOMA-IR)) at before and after HP eradication.
- Secondary Outcome Measures
Name Time Method HbA1c, lipid profile, C reactive protein, body weight, body mass index and waist circumference at before and after HP eradication.